Biomarkers in traumatic brain injury (TBI): a review

Abstract: Biomarkers can be broadly defined as qualitative or quantitative measurements that convey information on the physiopathological state of a subject at a certain time point or disease state. Biomarkers can indicate health, pathology, or response to treatment, including unwanted side effects. When used as outcomes in clinical trials, biomarkers act as surrogates or substitutes for clinically meaningful endpoints. Biomarkers of disease can be diagnostic (the identification of the nature and cause of a condition) or prognostic (predicting the likelihood of a person’s survival or outcome of a disease). In addition, genetic biomarkers can be used to quantify the risk of developing a certain disease. In the specific case of traumatic brain injury, surrogate blood biomarkers of imaging can improve the standard of care and reduce the costs of diagnosis. In addition, a prognostic role for biomarkers has been suggested in the case of post-traumatic epilepsy. Given the extensive literature on clinical biomarkers, we will focus herein on biomarkers which are present in peripheral body fluids such as saliva and blood. In particular, blood biomarkers, such as glial fibrillary acidic protein and salivary/blood S100B, will be discussed together with the use of nucleic acids (eg, DNA) collected from peripheral cells.

Keywords: peripheral markers, blood–brain barrier, post-traumatic epilepsy, fluid biomarkers, mild traumatic brain injury, neuroimaging

Introduction

According to the Food and Drug Administration (FDA), biomarkers can be broadly classified as a “characteristic that serves as an objective indicator of normal biological processes, pathogenic processes, or response to an exposure or intervention, including therapeutic interventions.” Biomarkers can be measured using molecular, histologic, radiographic, or physiologic tools. They can indicate health, pathology, or response to treatment, including unwanted side effects. They can act as surrogate endpoints in clinical trials or can, rarely, substitute for clinically meaningful endpoints. Biomarkers of disease can be diagnostic (identifying the nature and cause of a condition), prognostic (informing the likelihood of a person’s survival or outcome of a disease), or predictive (identifying individuals who are likely to experience a favorable or unfavorable effect from a specific treatment or exposure). In addition, genetic biomarkers are used to quantify the risk of developing a certain disease. For traumatic brain injury (TBI), brain-derived protein biomarkers are commonly used as discussed below.

TBIs are heterogeneous and can occur in a variety of ways. TBI can be classified by the mechanism of injury (eg, motor vehicle accidents, falls, and assaults), through clinical severity as graded by the Glasgow Coma Scale (GCS), or by the characterization of structural damage (for review, see the study by Maas et al and Buonora et al). The heterogeneity of the disease makes it difficult to accurately...
assess the level of trauma and predict the clinical outcome for individual patients. Furthermore, the majority of initial features of injury do not translate directly into long-term consequences. These considerations have made establishing a universal and comprehensive TBI assessment protocol a challenging hurdle in the field of health care. Generally, injuries are classified as mild, moderate, or severe depending on the GCS score (which utilizes motor, eye, and verbal responses to evaluate the patient’s level of consciousness), duration of unconsciousness, and duration of post-traumatic amnesia. TBI is characterized by an evolving pathology: time-dependent changes almost invariably follow the initial insult. For this reason, biomarker-based methods for diagnosis and prognosis can only be interpreted in the context of an evolving pathology. As discussed below, the understanding of this moving target is confounded by the fact that many biomarkers have complex kinetics relating to release from brain cells, transfer across the blood–brain barrier (BBB), and clearance from the peripheral blood. These kinetic behaviors are at best indirectly related to the pathology of TBI.

Several clinical-grade imaging modalities currently exist ranging from traditional computed tomography (CT) and MRI scans to more novel imaging techniques, such as susceptibility-weighted imaging, diffusion-weighted imaging, and diffusion tensor imaging. All have been utilized in the context of TBI identification and clinical management. In addition, imaging modalities, such as functional MRI, positron emission tomography, single-photon emission computed tomography, and magnetic resonance spectroscopy, provide insight into metabolic abnormalities, which may have resulted from TBI, providing yet another level of information that could aid in diagnosis and treatment. Serum and cerebrospinal fluid (CSF) markers have been developed as an alternative or synergistic complement to radiological investigations of TBI and its sequelae. These imaging and analytic modalities, when combined, will provide a future pathway toward improved clinical outcomes and enhanced power of clinical management for TBI patients.

Uncomplicated mild TBI (mTBI) is diagnosed if the patient has no post-TBI injuries detected by a noncontrast CT head scan. A diagnosis of complicated mTBI is made if the patient has evidence of an intracranial event, such as a subdural hematoma (SDH) or epidural hematoma (EDH), subarachnoid hemorrhage, intraparenchymal hemorrhage, or brain edema. The possibility of intracranial hemorrhages is an important consideration following mTBI and is the primary motivation for performing initial CT imaging studies. In these patients, symptoms of bleeding may not be present at the time of emergency room visit and are manifest only after appropriate imaging. SDH and EDH may change the course of clinical management, as these events mandate admission to an intensive care unit and often require neurosurgical intervention. SDH is not uncommon in mTBI sequelae and is often associated with the rupture of cerebral veins, causing progressive accumulation of blood in the subdural space. Subacute and chronic SDHs are relatively common in patients with mTBI, especially in the geriatric population and when anticoagulation is present for pre-existing conditions. It is important to accurately diagnose SDH, as an expanding mass lesion may necessitate surgery. Moreover, SDH is often associated with breakdown of the BBB, disproportionate tissue inflammation, and cerebral edema, which may cause progressive neurological deterioration. These are some of the most common rationales to use surrogate biomarkers because their appearance in blood and other fluids is facilitated or caused by BBB disruption. EDHs are caused by acceleration–deceleration injuries and can be commonly ascribed to the rupture of a meningeal artery. The timely diagnosis of EDH is also of critical importance, as expanding hematomas may become life threatening, and progressive neurological deterioration, often after a lucid interval, require neurosurgical intervention. Again, this underscores the need for surrogate biomarkers when CT scans are unavailable or during transport from a remote location. Bleeding into the subarachnoid space after mTBI may also occur, but is less likely to require surgical intervention. Thus, it is critically important that acute intracranial pathology and bleeding are accurately diagnosed with a noninvasive biomarker-based test. Glial fibrillary acidic protein (GFAP), S100B, and UCHL-1 (see below) have all been used as surrogate markers of intracranial sequelae after TBI.

Predicting patient outcome following TBI is challenging and inaccurate when based solely on clinical presentation and radiological findings because patients with seemingly comparable injuries frequently have widely variable outcomes. As underscored in the introductory paragraphs, TBI additionally evolves with time, and the injury develops into two distinct phases, a primary injury phase and secondary injury phase. Notably, the relationship between the primary phase and the secondary phase is weak and inconsistent. The primary phase occurs as a direct consequence of the mechanical forces experienced during head impact, which can disrupt the brain parenchyma and affect the integrity of the BBB. This is followed by a systemic and neuroinflammatory response or secondary phase, which is mediated by peripheral immune cells and the activation of immunocompetent neural cells. Molecular mediators such as cytokines, growth factors, and adhesion molecules are released, causing the activation
of a complex network of pathways. The secondary injury phase can evolve over a period of hours to days and months following the primary injury. Some of these pathways are restorative in nature, while others contribute to metabolic dysregulation and hypoxic events secondary to brain swelling and edema.22–24

Nature and origin of biomarkers of TBI

Biomarkers of TBI are often measured in body fluids. Most of the data available today were obtained by measurements in CSF or blood (serum or plasma).12,17,25,26 More recently, saliva has been analyzed to show that the biomarker S100B can be measured at levels comparable with blood.27–29 In severe TBI, when access to CSF is possible, markers can be measured from the ventricles or lumbar spine.30–32 When genetic testing is the goal (see text below), DNA is extracted from cheek cells, circulating white blood cells, or isolation of free DNA “floating” in serum or (less commonly) CSF. For RNA, the favored source is the pellet of leukocytes obtained by centrifugation of whole blood, but cell-free RNA found in serum or plasma, in association with exosomes or other molecular complexes, may also provide valuable information. The cell type-specific origin of RNAs can be studied via prior separation of cells by traditional cell sorting techniques33 or by immune-affinity techniques using cell surface markers found in exosomes, which can identify their cell of origin.

A family of physiologic biomarkers, such as electroencephalogram recordings after TBI, has received notable attention.34,35 While this is not the main topic of this review, it is important to understand how the complexity of TBI has led to an equally intricate field of diagnostic and prognostic tools. In addition, recent emphasis on nonblood-derived TBI biomarkers includes genetic material and imaging findings. For the latter see the study by Zhang et al, where a review of imaging findings from TBI is presented and radiologic findings are discussed in the context of brain-derived blood biomarkers. The following exemplify the role of genetic biomarkers in the diagnostic and prognostic approach to TBI (reviewed in the articles by McAllister,36 Lipsky and Lin,37 Bennet et al,38 and Cotter et al,39 also see the articles by Wong and Langley40 and Meng et al41 for recent findings with genomic/genetic approaches for TBI). A discussion of gene discovery based on systems biology is also available.42

Genetic biomarkers of TBI and post-traumatic epilepsy (PTE)

The genes involved in the pathology of TBI belong to two broad categories: those that control and determine the extent of the injury (eg, inflammatory cytokines and their receptors and antagonists) and those that affect neuronal plasticity (eg, brain-derived neurotrophic factor). A new category expands these to genes involved in the cognitive process (eg, catecholamine genes).43,44 Although not well studied, the properties of dopamine (DA) may contribute to oxidative injury after TBI. In addition, chronic disruption of a number of DA-related proteins, as well as DA neurotransmission, in the striatum has been reported in experimental TBI models.45,46 Moreover, human studies using single-photon emission CT indicate that DAT expression is reduced chronically after TBI.47 In general, prognostic genetic markers are used to predict downstream pathologies and comorbidities, as in PTE.48 PTE can be characterized by a “silent” period that can last months or years. A more comprehensive understanding of predictors of epilepsy may fill a substantial knowledge gap: today, selection of treatment is still decided upon by “trial-and-error” because we lack reliable tools, such as biomarkers, to identify individuals most likely to respond to any specific intervention or individuals at risk of developing seizure disorders.49

Individuals who suffered a TBI were exposed to an increased risk of developing epilepsy. When compared with patients with no brain injury, the relative risk (RR) of epilepsy has been found to be two times higher after mTBI (RR 2.22, 95% CI 2.07–2.38) and seven times higher after severe brain injury (RR 7.40, 95% CI 6.16–8.89).48 One mechanism that has emerged as having potentially prognostic importance after TBI is systemic or brain inflammation. In the field of PTE, most genetic associations examined have been single-nucleotide polymorphisms (SNPs), a common variation within a population that can be defined as a variation of a single nucleotide, adenine (A), guanine (G), thymine (T), or cytosine (C), between individuals. A recent finding shows that an SNP of IL-1β influences the probability of PTE after TBI.49 More specifically, the rs1143634 polymorphism favored the development of PTE by affecting the CSF-to-serum ratio of this cytokine. The TT variant in rs1143634 protected from PTE. Similar dual effects of SNPs were found for GAD1 and A1AR, encoding the glutamic acid decarboxylase gene and the gene for adenosine A1 receptor, respectively.39

Pathologic significance of serum biomarkers: S100B

A common issue when dealing with biomarkers of brain pathology or health is the origin of the marker itself. Molecules, such as the glial protein S100B and neuron-specific enolase (NSE), were originally believed to directly relate to the extent of brain damage after an insult.50–52 One of the
It is not completely clear how these proteins leave the injured brain and enter the blood. BBB disruption release independent of BBB integrity, as well as passage through the newly discovered glymphatic system, has been suggested as possible routes for markers appearance in blood or other biological fluids. Presumably, these proteins are first released in the brain extracellular space, a component difficult to access for repeated sampling, before being transported to the cerebral spinal fluid (CSF) where a passive diffusion from CSF to blood occurs. Some but not all these proteins are already present in the CSF and interstitial fluid, which when in communication with blood can elevate markers levels in the absence of release or ex novo synthesis.

Things are further complicated because results from different laboratories are difficult to reconcile. For example, a discrepancy between the albumin coefficient (an indicator of BBB disruption) and serum S100B (a putative reporter of BBB function) has been shown. Others found a concordance between serum levels of S100B and CSF:blood albumin ratios. A weakness in assessing BBB integrity using this albumin quotient \( Q_A \) is that patients suffering from TBI sometimes exhibit intraventricular hemorrhage. Intraventricular hemorrhage implies albumin content in the CSF, not originating from a disintegrated BBB itself but from injured vessels, a fact that might disturb the efficacy of \( Q_A \) to assess BBB integrity.

The hypothesis of a glymphatic system has received both support (eg, a study by Plog and Nedergaard) and criticism. The glymphatic system has been suggested as a mediator of biomarkers extravasation after TBI. There are several problems with this hypothesis in the context of findings by many others. The main reason for skepticism about the interpretation of the findings by Plog et al is that previous studies reported that the biomarker S100B is increased within minutes after BBB disruption (carotid–jugular measures during endarterectomy, venous blood after osmotic disruption), while the results of Plog et al were obtained at much later time points. Given also the fact that the passage in systemic circulation of S100B accurately predicts gadolinium extravasation across a leaky BBB and that S100B in serum correlates with albumin CSF:blood ratio (see discussion above), it is likely that the preferred pathway in human subjects is trans-BBB rather than the slower glymphatic pathway.

A major confounding factor for the correct interpretation of blood biomarkers related to the central nervous system (CNS) is that most of these biomarkers are expressed to varying degrees outside the CNS. Even in early work with S100B and cardiothoracic surgery, it was noted that the levels measured were inconsistent with an exclusive brain origin, but rather pointed to a peripheral source. While S100B is present in skin and fat tissue, the values measured were exorbitant even when considering a full contribution of CNS and all extracranial sources (see Table 1). In fact, by calculating the total S100B levels in a healthy individual, it was concluded that the highest value including all extracranial sources was <2 ng/mL. During cardiothoracic surgeries, S100B was measured at the surgical site (chest cavity) and concomitantly in serum; S100B levels were found to be almost 100-fold higher in pericardial fluid and two-fold elevated in serum compared with the ceiling value mentioned above. To address this, an effort was made to study the possibility of cross-reactivity of the test for S100B; the data demonstrated that at least with the enzyme-linked immunosorbent assay protocol used in this article, the values attributed to S100B were not due to the protein itself but other epitopes that the antibody cross-reacted with. Because all the spurious epitopes were found in relatively large protein, a filtration step (<50 kDa) was sufficient to remove the contribution of non-S100B antigens. The problem of cross-reactivity of tests based on immunodetection is likely to be an issue across different platforms and regardless of the antigen being measured. As also detailed above, the presence of S100B in saliva is being exploited to address this issue because saliva has a fairly low-molecular-weight cutoff, which allows S100B but not cross-reacting epitopes to be represented after capillary filtration.

The contribution of fat tissue to blood levels of S100B was also studied in a large number of patients to show that even though fat expresses the protein, levels in blood are not directly affected, perhaps owing to the reduced capillary network available for protein diffusion in fat compared with other organs and tissues. Finally, the contribution of skin S100B was found to be problematic in TBI diagnosis, but with the use of a simple algorithm this could be accounted for and adjusted to show levels adjusted by skin color.

**Markers of blast vs traditional TBI**

Extracranial contributions to overall biomarker levels in blood are important confounder in cases of polytrauma.
Polytrauma is common in military populations after blast exposure. A rise in terrorism worldwide also fuels the polytrauma epidemic for civilian casualties. Blast-induced polytrauma poses a unique obstacle because the need for a TBI biomarker is confounded by the presence of injuries, which may increase biomarker levels in the absence of TBI.

As in the case of impact TBI, blast injury affects the BBB. A recent study reports a detailed characterization of BBB opening and recovery time course in a rodent model of blast exposure. Early and delayed BBB "openings" were documented as well, to show preference for the extravasation of low-molecular-weight (<70 kDa) tracers in blood. BBB disruption persisted for at least 6 hours postinjury, and barrier integrity recovered by 24 hours. These findings

---

**Table 1** Peripheral and brain S100B levels

<table>
<thead>
<tr>
<th>Volume of organ (cm³)</th>
<th>$\textbf{S}100\textbf{B}$ (ng/mg)</th>
<th>Estimated $\textbf{S}100\textbf{B}$ (ng)</th>
<th>% of CNS total</th>
<th>Maximum $\textbf{S}100\textbf{B}$ serum levels (ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>1,690</td>
<td>1</td>
<td>2,113</td>
<td>0.02</td>
</tr>
<tr>
<td>Kidney</td>
<td>280</td>
<td>0</td>
<td>70</td>
<td>0.00</td>
</tr>
<tr>
<td>Lung</td>
<td>1,172</td>
<td>4</td>
<td>4,395</td>
<td>0.03</td>
</tr>
<tr>
<td>Muscle</td>
<td>35,000</td>
<td>3</td>
<td>105,000</td>
<td>0.79</td>
</tr>
<tr>
<td>Pancreas</td>
<td>77</td>
<td>2</td>
<td>154</td>
<td>0.00</td>
</tr>
<tr>
<td>Fat</td>
<td>10,000</td>
<td>5</td>
<td>54,600</td>
<td>0.41</td>
</tr>
<tr>
<td>Brain</td>
<td>1,400</td>
<td>96</td>
<td>133,700</td>
<td>1.00</td>
</tr>
<tr>
<td>Stomach</td>
<td>154</td>
<td>3</td>
<td>462</td>
<td>0.00</td>
</tr>
<tr>
<td>Skin</td>
<td>7,800</td>
<td>3</td>
<td>21,450</td>
<td>0.16</td>
</tr>
</tbody>
</table>

**B**: Contribution of CNS and peripheral sources to S100B levels

<table>
<thead>
<tr>
<th>Extracranial</th>
<th>CNS and peripheral sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extracranial Breast</td>
<td>Myoepithelial cells</td>
</tr>
<tr>
<td>Extracranial Cerebellum</td>
<td>Glial cells</td>
</tr>
<tr>
<td>Extracranial Cerebral cortex</td>
<td>Glial cells</td>
</tr>
<tr>
<td>Extracranial Cerebral cortex</td>
<td>Neuripil</td>
</tr>
<tr>
<td>Extracranial Hippocampus</td>
<td>Glial cells</td>
</tr>
<tr>
<td>Extracranial Skin</td>
<td>Langerhans</td>
</tr>
<tr>
<td>Extracranial Peripheral nerve</td>
<td></td>
</tr>
<tr>
<td>Extracranial Adipocytes</td>
<td></td>
</tr>
<tr>
<td>Extracranial Adrenal gland</td>
<td>Glandular cells</td>
</tr>
<tr>
<td>Extracranial Bone marrow</td>
<td>Hematopoietic cells</td>
</tr>
<tr>
<td>Extracranial Breast</td>
<td></td>
</tr>
<tr>
<td>Extracranial Bronchus</td>
<td>Epithelial cells</td>
</tr>
<tr>
<td>Extracranial Cerebral cortex</td>
<td>Endothelial cells</td>
</tr>
<tr>
<td>Extracranial Intestine</td>
<td></td>
</tr>
<tr>
<td>Extracranial Esophagus</td>
<td>Squamous epithelial cells</td>
</tr>
<tr>
<td>Extracranial Heart muscle</td>
<td>Myocytes</td>
</tr>
<tr>
<td>Extracranial Kidney</td>
<td></td>
</tr>
<tr>
<td>Extracranial Lung</td>
<td></td>
</tr>
<tr>
<td>Extracranial Lymph node</td>
<td></td>
</tr>
<tr>
<td>Extracranial Ovary</td>
<td>Follicle cells</td>
</tr>
<tr>
<td>Extracranial Pancreas</td>
<td></td>
</tr>
<tr>
<td>Extracranial Parathyroid gland</td>
<td>Glandular cells</td>
</tr>
<tr>
<td>Extracranial Salivary gland</td>
<td>Glandular cells</td>
</tr>
<tr>
<td>Extracranial Seminal vesicle</td>
<td>Glandular cells</td>
</tr>
<tr>
<td>Extracranial Skeletal muscle</td>
<td>Myocytes</td>
</tr>
<tr>
<td>Extracranial Small intestine</td>
<td>Glandular cells</td>
</tr>
<tr>
<td>Extracranial Spleen</td>
<td></td>
</tr>
<tr>
<td>Extracranial Testis</td>
<td></td>
</tr>
<tr>
<td>Extracranial Thyroid gland</td>
<td>Glandular cells</td>
</tr>
<tr>
<td>Extracranial Tonsil</td>
<td>Germinal center cells</td>
</tr>
<tr>
<td>Extracranial Vagina</td>
<td>Squamous epithelial cells</td>
</tr>
</tbody>
</table>

are overall in agreement with nonblast models of TBI, in which BBB opening occurs transiently and returns to control levels. In addition, these animal model findings correlate well with the appearance of blood biomarkers related to BBB dysfunction in human studies. S100B was studied in a porcine model of blast injury: the early increase was not affected by the presence of systemic injuries, suggesting that in the case of impact TBI, S100B can be used as a surrogate marker of imaging. Opportunities for improvements in the diagnostic characterization of TBI come from progress in the fields of blood or salivary biomarkers. These technologies are at varying stages of maturity in terms of integration into TBI clinical care: some, such as genomic stratification for therapy and outcome prognostication, are at a very early stage, whereas others, such as use of the blood biomarker S100B to stratify patients for CT imaging during the acute phase, have already been integrated into some clinical guidelines, although not widely accepted.

**Kinetics of biomarkers**

One modern approach for identifying the presence or absence of pathophysiological changes after a head impact is the qualitative or quantitative determination of biomarkers in bodily fluids (ie, serum, saliva, CSF). Many of these biomarkers are believed to have a patient-independent kinetic behavior in the acute and chronic postinjury phases, with changes in serum biomarker levels presumed to depend mainly on source concentration and tissue of origin. It should be understood, however, that these biomarkers do not all present themselves at the same time after injury in every case, but that a biomarker’s kinetic distribution is heavily dependent on biophysical properties of the marker itself (ie, molecular weight), as well as on the anatomical and physiological characteristics of the individual (ie, glomerular filtration rate, age, gender, and skin pigmentation).

A noteworthy example is seen in the temporal kinetics of S100B and GFAP shown in Figure 1A. In this example, S100B has a sharp rise within minutes after injury and returns to homeostatic levels around 1–2 hours postinjury. In contrast, abnormal serum GFAP levels persist for days after the initial event. This chart fails to emphasize the contribution of physiological variables to biomarker kinetics, however. Using a physiologically based pharmacokinetic model for biomarker distribution in blood, it was shown that this time-dependent distribution is largely based on the molecular weight of S100B and GFAP (10.7 kDa and 50.0 kDa, respectively) rather than the origin of the maker itself, as suggested in the study by Maas et al. We have shown that the larger molecular weight of GFAP lends to a reduced filtration by the kidneys, and thus, a longer duration of pathological serum levels after injury. These differences in postinjury serum levels are further confounded by the anatomical and physiological properties of individual patients because glomerular filtration rate is governed by a formula, which takes into account age, gender, and ethnicity. The data in Figure 1B show the results of a simulation performed according to a kinetic model for biomarkers. In particular, the predicted kinetic behavior of S100B and GFAP after BBB disruption is shown together with a quantitative analysis of kidney excretion of these biomarkers (Figure 1C). In this model, the barrier is “open” to 25% of free diffusion rate (to simulate an instantaneous BBB disruption event), and recovery of barrier integrity occurs 2 hours after injury. Additionally, the curve for serum GFAP is artificially increased to match the peak serum S100B, so that time-dependent properties predominate. As previously demonstrated in the study by Dadas et al, the half-life of GFAP in blood is considerably longer than S100B, owing to the larger molecular weight of the biomarker.

**Markers of brain damage vs markers of BBB disruption**

An early finding with S100B was that this blood biomarker was elevated even when brain damage was not present. It was then shown that families of soluble protein biomarkers are also indicators of BBB disruption rather than brain damage (Figure 2). This has important consequences in many clinical situations or preclinical models of systemic or brain disease. Most importantly, the usual diagnostic definitions of “positive” or “negative” predictive values need to be reformulated. In fact, in mTBI and in the absence of parenchymal lesions, the markers report the status of the BBB rather than “brain damage.” Thus, a positive predictive value should refer to contrast MRI or other sequences detecting BBB dysfunction. For many reasons, a comparison between blood markers and MRI has never been systematically done in TBI patients (but see the study by Thelin et al and Linsenmaier et al); however, it has been studied in other pathologies. For example, the relationship between body mass index (BMI) and serum S100B values was shown not to be solely due to extracranial sources but rather reflects the clinical reality of impaired BBB integrity in morbidly obese people; factors, such as high blood pressure or metabolic disease, contribute to cerebrovascular dysfunction or BBB integrity.
An important fact to keep in mind when analyzing blood biomarker data is the difference between a patient-specific relative increase and an increase above normal population values. For example, in one of the seminal papers showing a correlation between BMI and serum S100B,96 if one uses the normal cutoff for the test used (0.12 ng/mL), only three subjects were above the normal cutoff value, and all three were severely obese (BMI ≥35). The authors presented other data
elsewhere but because the subjects were the same, the conclusions drawn are essentially the same. An important factor to consider is the presence of comorbidities of systemic disease that may impact the BBB without directly affecting the brain. In another study, no effect of BMI on S100B was seen and only diabetic patients exhibited a high serum value.

In polytrauma patients without TBI, the signal from biomarkers of the BBB may be elevated by conditions affecting the BBB such as hypotension (shock), sepsis, and pain. In an animal model of blast injury, a major finding was that BBB disruption, highlighted by a reduction in endothelial barrier antigen+ vessels at 7 days after injury, plays a distinct role in blast injury pathology. These effects on BBB were larger after blast with extracranial damage. Further suggestive of a role for the BBB (and not TBI) in polytrauma is the fact that similar to S100B, levels of GFAP and UCH-L1 were not able to distinguish patients with CT-negative mTBI from patients with orthopedic trauma.

**Biomarkers in saliva**

The onset of TBI triggers an intricate sequence of physical consequences and pathophysiological responses. These sequelae can be acute (ie, intracranial lesions and BBB disruption) or chronic (ie, autoimmune response and neurodegeneration) and may occur in traumas of any severity. A critical factor in the diagnosis and management of TBI is the ability to detect these sequelae in a quick, reliable, and low-risk manner, with the ideal modality also being affordable and portable for point-of-care (POC) assessment. POC devices currently in development use blood from which platelets or red blood cells require a complicated removal process before an analysis can be completed. In addition, circumstances exist when testing of blood is problematic. For example, blood draws cannot be performed when paramedics or trained personnel are not available. Furthermore, risk of caretaker’s infection from blood products and the time and equipment necessary to separate blood components make

---

Figure 2 Behavior of brain biomarkers under conditions of intact (A) or disrupted (B) BBB. See text for details.

**Abbreviation:** BBB, blood–brain barrier.
Biomarkers in traumatic brain injury

blood diagnosis challenging. It was recently shown that saliva can act as a valid surrogate for blood for several biomarkers including S100B.27,80,99,100

The use of saliva for diagnostics has many advantages, including simple and noninvasive collection method, the fact that this body fluid does not require preprocessing, centrifugation, etc, bears minimal or no risk of contracting infections, and provides easy, low-cost storage. One of the problems, however, is that no clear-cut understanding of biomarker dynamic passage from blood to saliva was available. We have tackled the first problem as follows: we first developed a mathematical model to describe the passage of protein from systemic circulation into saliva.78,80 We used a physiologically based pharmacokinetic model to describe the distribution of brain-derived biomarkers in blood.78,101 Its main structure was expanded to include a new compartment, namely an idealized salivary gland receiving its vascular supply from the external carotid artery. The venous output can be mimicked according to the properties of jugular vein exiting the brain. Recent work102 showed that the whole saliva (WS) proteome when compared with the plasma proteome displays a larger proportion (14.5%) of low-molecular-weight proteins (<20 kDa) in contrast to only 7% for the plasma proteome. The highest fraction of proteins found in WS and blood range from 20 to 40 kDa (26%), whereas the 40 to 60 kDa range is the largest fraction for plasma (18%). This is consistent with selective permeability between blood and saliva for low-molecular-weight proteins. According to these considerations, of the commonly used protein biomarkers, only S100B and UCHL-1 are predicted to appear in saliva after an initial step of extravasation from brain to blood. The salivary “barrier” appears to be more selective than the BBB even though in reality leakage from brain to blood occurs across a disrupted barrier, while extravasation in saliva is across a healthy tissue.

Conclusion

Biomarkers are essential diagnostic and prognostic tools in a variety of neurological diseases, including TBI (eg, Figure 3). While the field of biomarker discovery has produced a plethora of molecular and genetic signatures, it still remains necessary to exactly define the nature, origin, and pathophysiological correlates of biomarkers or biomarker families. Historically, biomarkers were measured in blood or CSF; today, the use of saliva or other unconventional body fluids is gaining momentum, owing to the ease of access to secreted or filtered body fluids.

Disclosure

DJ and AD are employed by FloTBI, a company dealing with biomarker discovery. DJ and AD held an equity position.

Figure 3 Summary of blood biomarkers used in TBI.

Abbreviations: EEG, electroencephalogram; GFAP, glial fibrillary acidic protein; PTE, post-traumatic epilepsy; TBI, traumatic brain injury.
in FloTBI. The authors report no other conflicts of interest in this work.

References

3. Buonora JE, Yarnell AM, Lazarus RC, et al. Multivariate analysis of 2998 in FloTBI. The authors report no other conflicts of interest in this work.

References


